Phase 1 Study With KIN-1901 in Healthy Subjects and Subjects With Ankylosing Spondylitis
Status:
Completed
Trial end date:
2020-04-07
Target enrollment:
Participant gender:
Summary
This study is intended to treat ankylosing spondylitis (AS). AS is a form of arthritis that
primarily affects the spine. It is characterized by inflammation of the spinal joints that
can lead to severe pain, and in more advanced cases, ankylosis (sections of the spine fuse in
a fixed, immobile position). The study will be an ascending single and multiple-dose study to
evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous
KIN-1901 in healthy subjects and subjects with AS.